ArticleClinical pharmacokinetics2024

Use of a PK/PD Model to Select Cetagliptin Dosages for Patients with Type 2 Diabetes in Phase 3 Trials.

Jinmiao Lu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.